NASDAQ:IDYAIDEAYA Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IDEAYA Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.51 +0.72 (+6.11 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$11.61Now: $12.51▼$12.9550-Day Range$11.30MA: $13.43▼$18.5752-Week Range$2.95Now: $12.51▼$19.97Volume124,600 shsAverage Volume207,537 shsMarket Capitalization$255.20 millionP/E RatioN/ADividend YieldN/ABeta2.68 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.40, IDEAYA Biosciences has a potential upside of 87.1% from its current price of $12.51.Amount of Analyst CoverageIDEAYA Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesIDEAYA Biosciences has received 56 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIDEAYA Biosciences has received 50 “underperform” votes. (Add your “underperform” vote.)Community SentimentIDEAYA Biosciences has received 52.83% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IDEAYA Biosciences and other stocks. Vote “Outperform” if you believe IDYA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IDYA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have bought 1,687.96% more of their company's stock than they have sold. Specifically, they have bought $3,411,121.00 in company stock and sold $190,783.00 in company stock.Percentage Held by InsidersOnly 20.70% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions49.87% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from $0.04 to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.02 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IDYA Previous Symbol CUSIPN/A CIKN/A Webwww.ideayabio.com Phone650-443-6209Debt Debt-to-Equity Ratio0.06 Current Ratio12.18 Quick Ratio12.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio312.75 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book2.53Profitability EPS (Most Recent Fiscal Year)($3.36) Net Income$-41,970,000.00 Net MarginsN/A Return on Equity-42.28% Return on Assets-37.79%Miscellaneous Employees56 Outstanding Shares20,400,000Market Cap$255.20 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable $12.51 +0.72 (+6.11 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IDYA News and Ratings via Email Sign-up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions How has IDEAYA Biosciences' stock been impacted by COVID-19 (Coronavirus)? IDEAYA Biosciences' stock was trading at $4.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IDYA stock has increased by 157.9% and is now trading at $12.51. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of IDEAYA Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IDEAYA Biosciences. When is IDEAYA Biosciences' next earnings date? IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for IDEAYA Biosciences. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences (NASDAQ:IDYA) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.02. View IDEAYA Biosciences' earnings history. What price target have analysts set for IDYA? 5 brokers have issued 1 year target prices for IDEAYA Biosciences' stock. Their forecasts range from $12.00 to $30.00. On average, they expect IDEAYA Biosciences' share price to reach $23.40 in the next twelve months. This suggests a possible upside of 87.1% from the stock's current price. View analysts' price targets for IDEAYA Biosciences. Has IDEAYA Biosciences been receiving favorable news coverage? Headlines about IDYA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEAYA Biosciences earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about IDEAYA Biosciences. Are investors shorting IDEAYA Biosciences? IDEAYA Biosciences saw a drop in short interest in July. As of July 31st, there was short interest totaling 1,270,000 shares, a drop of 23.5% from the July 15th total of 1,660,000 shares. Based on an average trading volume of 281,300 shares, the days-to-cover ratio is currently 4.5 days. Approximately 9.9% of the company's shares are sold short. View IDEAYA Biosciences' Short Interest. Who are some of IDEAYA Biosciences' key competitors? Some companies that are related to IDEAYA Biosciences include Phathom Pharmaceuticals (PHAT), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), I-Mab (ARQT), Generation Bio (GBIO), BioXcel Therapeutics (BTAI), Aimmune Therapeutics (AIMT), Athenex (ATNX), Gossamer Bio (GOSS), Stoke Therapeutics (STOK), Legend Biotech (PLRX), DiaMedica Therapeutics (DMCAF), Repare Therapeutics (RPTX), Rhythm Pharmaceuticals (RYTM) and Phibro Animal Health (PAHC). View all competitors. What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include ACADIA Pharmaceuticals (ACAD), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Crispr Therapeutics (CRSP), TapImmune (MRKR), Aurinia Pharmaceuticals (AUPH), BioCryst Pharmaceuticals (BCRX), ABIOMED (ABMD), Aeglea Bio Therapeutics (AGLE) and Amarin (AMRN). Who are IDEAYA Biosciences' key executives? IDEAYA Biosciences' management team includes the following people: Mr. Yujiro S. Hata, Co-Founder, CEO, Pres & Director (Age 45)Mr. Jeffrey Hager, Sr. VP, CTO, Head of Target Discovery & External Innovation (Age 55)Mr. Paul A. Stone, Sr. VP, Gen. Counsel & Head of Operations (Age 55)Mr. Michael P. Dillon, Sr. VP, Chief Scientific Officer & Head of Research (Age 52)Dr. Julie Hambleton, Sr. VP, Chief Medical Officer & Head of Devel. (Age 61) When did IDEAYA Biosciences IPO? (IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO. What is IDEAYA Biosciences' stock symbol? IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA." Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.05%), UBS Group AG (0.02%) and Strs Ohio (0.02%). Company insiders that own IDEAYA Biosciences stock include Alexandria Venture Investments, Bvf Partners L P/Il, Jason Throne, Mark Lackner, Paul A Stone, Timothy M Shannon and Value Fund L P Biotechnology. View institutional ownership trends for IDEAYA Biosciences. Which institutional investors are buying IDEAYA Biosciences stock? IDYA stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, UBS Group AG, and Strs Ohio. Company insiders that have bought IDEAYA Biosciences stock in the last two years include Alexandria Venture Investments, Bvf Partners L P/Il, Paul A Stone, Timothy M Shannon, and Value Fund L P Biotechnology. View insider buying and selling activity for IDEAYA Biosciences. How do I buy shares of IDEAYA Biosciences? Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is IDEAYA Biosciences' stock price today? One share of IDYA stock can currently be purchased for approximately $12.51. How big of a company is IDEAYA Biosciences? IDEAYA Biosciences has a market capitalization of $255.20 million. The company earns $-41,970,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. IDEAYA Biosciences employs 56 workers across the globe. What is IDEAYA Biosciences' official website? The official website for IDEAYA Biosciences is www.ideayabio.com. How can I contact IDEAYA Biosciences? IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-6209 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
